Patient preference-weighted assessments using the ASCO value framework in recurrent, platinum-sensitive ovarian cancer.
Publication
, Conference
Foote, J; Liang, M; Secord, AA; Cohn, DE; Havrilesky, LJ
Published in: Journal of Clinical Oncology
May 20, 2016
Duke Scholars
Published In
Journal of Clinical Oncology
DOI
EISSN
1527-7755
ISSN
0732-183X
Publication Date
May 20, 2016
Volume
34
Issue
15_suppl
Start / End Page
6630 / 6630
Publisher
American Society of Clinical Oncology (ASCO)
Related Subject Headings
- Oncology & Carcinogenesis
- 3211 Oncology and carcinogenesis
- 1112 Oncology and Carcinogenesis
- 1103 Clinical Sciences
Citation
APA
Chicago
ICMJE
MLA
NLM
Foote, J., Liang, M., Secord, A. A., Cohn, D. E., & Havrilesky, L. J. (2016). Patient preference-weighted assessments using the ASCO value framework in recurrent, platinum-sensitive ovarian cancer. In Journal of Clinical Oncology (Vol. 34, pp. 6630–6630). American Society of Clinical Oncology (ASCO). https://doi.org/10.1200/jco.2016.34.15_suppl.6630
Foote, Jonathan, Margaret Liang, Angeles Alvarez Secord, David E. Cohn, and Laura Jean Havrilesky. “Patient preference-weighted assessments using the ASCO value framework in recurrent, platinum-sensitive ovarian cancer.” In Journal of Clinical Oncology, 34:6630–6630. American Society of Clinical Oncology (ASCO), 2016. https://doi.org/10.1200/jco.2016.34.15_suppl.6630.
Foote J, Liang M, Secord AA, Cohn DE, Havrilesky LJ. Patient preference-weighted assessments using the ASCO value framework in recurrent, platinum-sensitive ovarian cancer. In: Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2016. p. 6630–6630.
Foote, Jonathan, et al. “Patient preference-weighted assessments using the ASCO value framework in recurrent, platinum-sensitive ovarian cancer.” Journal of Clinical Oncology, vol. 34, no. 15_suppl, American Society of Clinical Oncology (ASCO), 2016, pp. 6630–6630. Crossref, doi:10.1200/jco.2016.34.15_suppl.6630.
Foote J, Liang M, Secord AA, Cohn DE, Havrilesky LJ. Patient preference-weighted assessments using the ASCO value framework in recurrent, platinum-sensitive ovarian cancer. Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2016. p. 6630–6630.
Published In
Journal of Clinical Oncology
DOI
EISSN
1527-7755
ISSN
0732-183X
Publication Date
May 20, 2016
Volume
34
Issue
15_suppl
Start / End Page
6630 / 6630
Publisher
American Society of Clinical Oncology (ASCO)
Related Subject Headings
- Oncology & Carcinogenesis
- 3211 Oncology and carcinogenesis
- 1112 Oncology and Carcinogenesis
- 1103 Clinical Sciences